AC Immune (ACIU) Total Non-Current Liabilities (2015 - 2026)
AC Immune (ACIU) posted quarterly Total Non-Current Liabilities of $17.4 billion for Q1 2026, up 91808.1% year-over-year from N/an in Q1 2025, and down 5.13% quarter-over-quarter from $18.4 billion in Q4 2025.
AC Immune (ACIU) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Total Non-Current Liabilities for 12 consecutive years, with $17.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 91808.1% year-over-year to $17.4 billion; the TTM figure through Mar 2026 stood at $17.4 billion (up 91808.1% YoY), while the FY2025 annual figure was $17.7 billion, up 86979.49% from the prior year.
- Total Non-Current Liabilities slipped to $17.4 billion in Q1 2026 per ACIU's latest filing, from $18.4 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $18.4 billion in Q4 2025 and bottomed at $2.0 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $3.4 billion across 5 years, with a median of $15.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 99.98% — and 2023, when it jumped 170677.33%.
- AC Immune's Total Non-Current Liabilities stood at $5.7 million in 2022, then surged by 170677.33% to $9.7 billion in 2023, then slumped by 99.79% to $20.3 million in 2024, then surged by 90231.36% to $18.4 billion in 2025, then retreated by 5.13% to $17.4 billion in 2026.
- Business Quant data shows ACIU's Total Non-Current Liabilities at $17.4 billion in Q1 2026, $18.4 billion in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 18.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.97 Mn |
| Mar 31, 2026 | 17.42 Bn |
| Dec 31, 2025 | 18.36 Bn |
| Sep 30, 2025 | 13.60 Mn |
| Jun 30, 2025 | 19.94 Mn |
| Mar 31, 2025 | 18.95 Mn |
| Dec 31, 2024 | 20.32 Mn |
| Sep 30, 2024 | 15.12 Mn |
| Jun 30, 2024 | 15.02 Mn |
| Mar 31, 2024 | 9.71 Mn |
| Dec 31, 2023 | 9.69 Bn |
| Sep 30, 2023 | 6.35 Mn |
| Jun 30, 2023 | 6.39 Mn |
| Mar 31, 2023 | 5.90 Mn |
| Dec 31, 2022 | 5.67 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 2.13 Bn |
| Mar 31, 2022 | 10.26 Bn |
| Dec 31, 2021 | 10.24 Bn |
| Sep 30, 2021 | 10.84 Bn |